Skip to main content

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

The Original Article was published on 26 August 2020

Correction: BMC Cancer 20, 806 (2020)

https://doi.org/10.1186/s12885-020-07264-8.

Following publication of the original article [1], the authors want to clarify the wording of two sentences.

In the line of the study procedures section “In total, 44 patients will be enrolled per group. After n = 18 patients have been enrolled to the HYPO- or CON-treatment arm, respectively, an interim efficacy analysis for the respective arm will be conducted based on the objective response rate (ORR) at 12 weeks after first durvalumab administration”, the sentence was refined to “[…] the objective response rate (ORR), when the 18th patient in each arm has undergone first radiographic assessment (at 12 weeks after first durvalumab administration).”

In the study endpoint section, in the line “The ORR evaluated 12 weeks after first durvalumab administration (according to RECIST 1.1) is set as the primary efficacy endpoint.”, the sentence changed to “The ORR according to RECIST 1.1 is set as the primary efficacy endpoint.”

References

  1. Bozorgmehr F, Chung I, Christopoulos P, et al. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer. 2020;20:806. https://doi.org/10.1186/s12885-020-07264-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Farastuk Bozorgmehr.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s12885-020-07264-8.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bozorgmehr, F., Chung, I., Christopoulos, P. et al. Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer 23, 740 (2023). https://doi.org/10.1186/s12885-023-11270-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-023-11270-x